-
12-Month OS Reaches 54%: Microbiome-Based Therapy MAAT013 Addresses the Therapeutic Crisis in Refractory GI-aGVHD
At the recent Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), Professor Florent Malard from Sorbonne Université, lead of the Microbiome Research Project within the EBMT Cellular Therapy & Immunobiology Working Party, presented the final results of the ARES Phase III clinical trial. The presentation focused on the efficacy and safety…
-
Up to 13 Years of Follow-up: Integrated Analysis of Etuvetidigene Autotemcel Shows Sustained Clinical Benefit in WAS Patients
During the EBMT Annual Meeting, Dr. Francesca Ferrua from the IRCCS San Raffaele Scientific Institute presented an integrated analysis of the lentiviral hematopoietic stem and progenitor cell (HSPC) gene therapy, etuvetidigene autotemcel (ototemcel), for the treatment of Wiskott-Aldrich Syndrome (WAS). The report highlighted remarkable efficacy and safety outcomes with a follow-up period extending up to…
-
A Milestone in Gene Editing: Prof. Locatelli Presents Durable 6-Year Data for Exa-cel in Thalassemia and Sickle Cell Disease
At the EBMT 2026 Annual Meeting, Professor Franco Locatelli from Bambino Gesù Children’s Hospital presented long-term follow-up data for exagamglogene autotemcel (exa-cel), a CRISPR/Cas9-based gene-editing therapy. The study included patients with transfusion-dependent thalassemia (TDT) and sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs). With a median follow-up of over three years and some patients…
-
Voice of China at EBMT 2026 | Professor Shan Fu: Ultra-Low Dose Achieves 91.7% Complete Remission—IL-10 CAR-T Therapy Demonstrates the Potential of “Enhanced Efficacy with Reduced Dose”
From March 22 to 25, 2026, the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Madrid, Spain. As one of the most influential conferences in the field, the meeting brought together thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy.
-
Voice of China at EBMT | Professor Yanmin Zhao: Pre-Transplant Genetic MRD Monitoring Improves Risk Stratification in TP53-Mutated AML/MDS
From March 22 to 25, 2026, the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Madrid, Spain. As one of the most influential conferences in the field, the meeting brought together thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy.
-
Voice of China at EBMT | Dr. Jingjing Feng: Dual-Target CD19/BCMA CAR-T Therapy Opens New Hope for Neuromyelitis Optica Spectrum Disorder
From March 22 to 25, 2026, the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Madrid, Spain. As one of the most influential conferences in the field, the meeting brought together thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy.
-
Professor Ming Hou: From “Following” to “Leading”—Key Updates in the 2025 Chinese Guidelines for Adult Immune Thrombocytopenia
In March, as spring brings renewed vitality to Beijing, the 9th Beijing Conference on Thrombosis and Hemostasis, together with the 7th Beijing Hematologic Oncology and Immunology Summit Forum, was held from March 27 to 28, 2026. Centered on advances in the diagnosis and treatment of thrombotic and hemostatic disorders, as well as hematologic malignancies and…
-
Professor Liansheng Zhang: A Common Condition with Major Consequences—Current Challenges and New Strategies in the Management of Iron Deficiency Anemia
Iron deficiency anemia (IDA) is the most common nutritional deficiency and the leading cause of anemia worldwide. Despite the availability of well-established diagnostic methods, IDA is often underestimated in clinical practice as a “minor condition.”
Connecting Medical Expertise through Media